Side-by-side comparison of AI visibility scores, market position, and capabilities
Blockchain decentralized wireless marketplace (founded 2020); $3M seed (UOB/Signum/Fenbushi), 30+ wireless operator partners, 6M+ host locations, 14 LatAm countries expansion competing with Helium Mobile for distributed small cell infrastructure.
Airwaive is a blockchain-powered decentralized wireless broadband marketplace — privately held, founded in 2020 by CEO Jeff Yee (former ZTE and AT&T executive) and Bin Zhu (blockchain serial entrepreneur) — connecting wireless service providers with home and business owners who earn cryptocurrency rewards by hosting wireless access points, replacing traditional cell tower site acquisition with a distributed micro-location network model analogous to "Airbnb for wireless infrastructure." The company raised $3 million in seed funding in February 2022 led by UOB (United Overseas Bank) Venture Management and Signum Capital, with participation from blockchain-focused funds including Fenbushi Capital, Spartan Group, Fundamental Labs, and Digital Finance Group. Airwaive has grown to serve 30+ wireless operators with over 6 million potential host locations in its marketplace. The company expanded into 14 Latin American countries in 2024-2025, bringing thousands of new wireless network sites to operators in Brazil, Colombia, Argentina, and other markets where conventional cell tower deployment is prohibitively expensive relative to the economic returns of serving rural and suburban populations. Airwaive Visualize, a generative AI-powered tool for natural language telecom site acquisition and management, was launched to streamline the deployment process for wireless carriers evaluating and managing distributed small cell sites. The company partners with JDI Global, the hardware manufacturer behind the Helium IoT network, for the small cell equipment deployed at host locations.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.